Polaris is a modern hybrid-indica strain whose exact origins and development history remain undocumented. Breeders have not publicly confirmed the lineage beyond its genetic relationship to Death-Star, leaving the deeper heritage of the variety to stay largely mysterious. Due to this lack of formal documentation, there is no verified record of its development timeline or the specific breeding objectives that preceded its market entry.

The chemical profile of Polaris is defined by an extensive range of terpenes led by caryophyllene, limonene, and nerolidol, followed by humulene, myrcene, linalool, beta-pinene, pinene, caryophyllene-oxide, geraniol, guaiol, eucalyptol, camphene, alpha-terpinene, gamma-terpinene, ocimene, and terpinolene. This complex assembly suggests a nuanced sensory experience, though individual batch potency remains an estimated 20.5% THC and an estimated 0.04% CBD. Growers find the plant, which carries a moderate difficulty rating, capable of producing high yields over a 70-day flowering cycle in both indoor and outdoor environments.

Users typically report a combination of relaxed and focused effects, making the strain a practical choice for those managing pain, stress, or sleep-related concerns. While Polaris functions as a distinct hybrid-indica entity, there are currently no recorded notable offspring linked to the strain. Its utility relies on its balanced application for therapeutic use, though its long-term genetic legacy within the broader cannabis landscape is not yet established.